Advanced Solid Tumors, Metastatic Solid Tumors
Conditions
Keywords
Mogamulizumab (KW-0761), 14-135
Brief summary
The purpose of this study is to find out what effects, good and/or bad, KW-0761, an investigational drug, has on the patient and their cancer.
Interventions
BIOLOGICALMogamulizumab (KW-0761)
Sponsors
Kyowa Hakko Kirin Pharma, Inc.
Memorial Sloan Kettering Cancer Center
Study design
Allocation
NON_RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Informed Consent form signed by the subject. * Males and females 18 years or older at the time of dose initiation. * Histologically confirmed unresectable solid tumor malignancy with at least 1 measurable lesion. In the expansion phase, eligibility will be limited to metastatic triple negative breast cancer that has received prior taxane and anthracycline therapy; Metastatic NSCLC that is not ALK+ and does not have a EGFR sensitizing mutation; and metastatic gastric cancer * Previously treated for an advanced cancer and there are no curative therapy options available * Karnofsky Performance Status ≥70 in the 30 day baseline period immediately prior to dosing. * Evidence of adequate organ function by standard laboratory tests: * Serum creatinine (Cr) ≤1.5 X upper limit of normal (ULN) * Serum total and (T -Bil ) ≤1.5 X ULN (prior diagnosis or past history consistent with Gilbert's syndrome is an exception) * Serum aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤2.5 X ULN * Platelets (Plts) ≥ 100,000/μl * Hemoglobin (Hgb) ≥ 9.0 g/dL * Absolute neutrophil count (ANC) ≥1000/mm3 * All female subjects of childbearing age must be either surgically sterile, postmenopausal for at least 1 year, or using an acceptable method of contraception. Examples of adequate methods of contraception include abstinence, intrauterine device, hormonal contraception, use of spermicide and a condom by sexual partner, or partner with a vasectomy. Adequate contraception must be used from the beginning of the screening period until at least 16 weeks after the last dose of KW-0761. Male subjects with partners of childbearing potential must use a barrier method of contraception from the day of the first dose of KW-0761 until at least 16 weeks after the last dose. * Life expectancy \> 12 weeks * Previously treated for advanced cancer with no additional therapy options available known to prolong survival.
Exclusion criteria
* Evidence of clinically significant of central nervous system (CNS) metastases or symptomatic CNS metastases within 30 days prior to dosing. History of autoimmune disease, except for vitiligo, diabetes, and autoimmune thyroiditis. * A history of any major surgery within 6 weeks prior to dosing. * Any history of systemic anticancer therapy (standard or experimental) completed within 30 days prior to dosing, with the exception of palliative ablation of lesion(s) as long as measurable disease lesion(s) remain for evaluation of exploratory endpoints. * Any concomitant serious physical illness other than cancer (i.e., immune deficiency disease, bleeding disorder, etc.) within 1 year prior to dosing. * Any history of Stevens-Johnson syndrome. * Clinically significant heart disease, defined as NYHA Class III or IV. * Any allergic reaction to a previously administered monoclonal antibody or other therapeutic protein. * Any significant systemic infection within 4 weeks prior to dosing. * Pregnancy or breast-feeding. * An existing diagnosis of HIV, hepatitis B, hepatitis C, or any current laboratory findings or clinical signs and symptoms that suggest these conditions. * Subjects with active herpes simplex or herpes zoster. Subjects with a history of herpes zoster who have had an outbreak within the last year will also be excluded. Subjects on prophylaxis for herpes who started taking medication at least 30 days prior to study entry, should continue to take the prescribed medication for the duration of the study. * Unresolved immune- related adverse events following prior biological therapy * Use of any investigational drugs within 30 days prior to dosing. * Any condition that requires or is likely to require treatment with systemic corticosteroids within the Core Study Period and short term follow-up. * Subjects that have had a myocardial infarction within the last 6 months. * Subjects on any immunomodulatory drug.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Maximum Tolerated Dose (MTD) | 1 year | A standard 3+3 design will be utilized to determine the MTD. Four dose levels of KW-0761 will be investigated (0.5mg/kg, 1mg/kg, 3mg/kg, 10mg/kg). Patients will be treated in cohorts of size three to six and the dosage will be escalated if the clinical toxicity is acceptable. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Overall Response | 2 years | Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR. |
Countries
United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Cohort 1 (0.5 mg/kg KW-0761 IV) Patients will be enrolled to receive a weekly intravenous (IV) dose of KW-0761 ranging from 0.5 mg/kg to 10.0 mg/kg as feasible starting on Day 1 for 4 weeks. In the absence of toxicity or progression of disease, patients may continue receiving KW-0761 for up to 12 months. Subsequent treatment courses will consist of an infusion every other week. Following end of treatment or treatment completion date, a 24-week short term follow-up (STFU) period of observation will begin. Phase II of the study will enroll a total of 48 subjects, 16 patients in 3 tumor-specific expansion cohorts each treated at the RP2D (MTD, or highest dose tested in Phase I part of trial).
Mogamulizumab (KW-0761) | 3 |
| Cohort 2 (1.0 mg/kg KW-0761IV) Q2W Patients will be enrolled to receive a weekly intravenous (IV) dose of KW-0761 ranging from 0.5 mg/kg to 10.0 mg/kg as feasible starting on Day 1 for 4 weeks. In the absence of toxicity or progression of disease, patients may continue receiving KW-0761 for up to 12 months. Subsequent treatment courses will consist of an infusion every other week. Following end of treatment or treatment completion date, a 24-week short term follow-up (STFU) period of observation will begin. Phase II of the study will enroll a total of 48 subjects, 16 patients in 3 tumor-specific expansion cohorts each treated at the RP2D (MTD, or highest dose tested in Phase I part of trial).
Mogamulizumab (KW-0761) | 3 |
| Cohort 3 (3.0mg/kg KW-0761IV) Patients will be enrolled to receive a weekly intravenous (IV) dose of KW-0761 ranging from 0.5 mg/kg to 10.0 mg/kg as feasible starting on Day 1 for 4 weeks. In the absence of toxicity or progression of disease, patients may continue receiving KW-0761 for up to 12 months. Subsequent treatment courses will consist of an infusion every other week. Following end of treatment or treatment completion date, a 24-week short term follow-up (STFU) period of observation will begin. Phase II of the study will enroll a total of 48 subjects, 16 patients in 3 tumor-specific expansion cohorts each treated at the RP2D (MTD, or highest dose tested in Phase I part of trial).
Mogamulizumab (KW-0761) | 5 |
| Cohort 4 (10.0mg/kg KW-0761IV) Patients will be enrolled to receive a weekly intravenous (IV) dose of KW-0761 ranging from 0.5 mg/kg to 10.0 mg/kg as feasible starting on Day 1 for 4 weeks. In the absence of toxicity or progression of disease, patients may continue receiving KW-0761 for up to 12 months. Subsequent treatment courses will consist of an infusion every other week. Following end of treatment or treatment completion date, a 24-week short term follow-up (STFU) period of observation will begin. Phase II of the study will enroll a total of 48 subjects, 16 patients in 3 tumor-specific expansion cohorts each treated at the RP2D (MTD, or highest dose tested in Phase I part of trial).
Mogamulizumab (KW-0761) | 6 |
| Total | 17 |
Baseline characteristics
| Characteristic | Cohort 1 (0.5 mg/kg KW-0761 IV) | Total | Cohort 4 (10.0mg/kg KW-0761IV) | Cohort 3 (3.0mg/kg KW-0761IV) | Cohort 2 (1.0 mg/kg KW-0761IV) Q2W |
|---|---|---|---|---|---|
| Age, Continuous | 55.3 years | 58.7 years | 58.7 years | 57 years | 58.3 years |
| Ethnicity (NIH/OMB) Hispanic or Latino | 3 Participants | 16 Participants | 5 Participants | 5 Participants | 3 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 0 Participants | 1 Participants | 1 Participants | 0 Participants | 0 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Asian | 0 Participants | 1 Participants | 0 Participants | 1 Participants | 0 Participants |
| Race (NIH/OMB) Black or African American | 0 Participants | 1 Participants | 1 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) More than one race | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 0 Participants | 1 Participants | 1 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) White | 3 Participants | 14 Participants | 4 Participants | 4 Participants | 3 Participants |
| Region of Enrollment United States | 3 Participants | 17 Participants | 6 Participants | 5 Participants | 3 Participants |
| Sex: Female, Male Female | 0 Participants | 6 Participants | 3 Participants | 1 Participants | 2 Participants |
| Sex: Female, Male Male | 3 Participants | 11 Participants | 3 Participants | 4 Participants | 1 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk | EG003 affected / at risk |
|---|---|---|---|---|
| deaths Total, all-cause mortality | 3 / 3 | 3 / 3 | 5 / 5 | 6 / 6 |
| other Total, other adverse events | 3 / 3 | 3 / 3 | 5 / 5 | 6 / 6 |
| serious Total, serious adverse events | 2 / 3 | 2 / 3 | 2 / 5 | 2 / 6 |
Outcome results
Primary
Maximum Tolerated Dose (MTD)
A standard 3+3 design will be utilized to determine the MTD. Four dose levels of KW-0761 will be investigated (0.5mg/kg, 1mg/kg, 3mg/kg, 10mg/kg). Patients will be treated in cohorts of size three to six and the dosage will be escalated if the clinical toxicity is acceptable.
Time frame: 1 year
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Mogamulizumab (KW-0761) | Maximum Tolerated Dose (MTD) | 10.0 mg/kg KW-0761IV |
Secondary
Overall Response
Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.
Time frame: 2 years
| Arm | Measure | Category | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Mogamulizumab (KW-0761) | Overall Response | Progressive disease | 1 Participants |
| Mogamulizumab (KW-0761) | Overall Response | Not entered | 0 Participants |
| Mogamulizumab (KW-0761) | Overall Response | Stable disease | 2 Participants |
| Cohort 2 (1.0 mg/kg KW-0761IV) Q2W | Overall Response | Progressive disease | 0 Participants |
| Cohort 2 (1.0 mg/kg KW-0761IV) Q2W | Overall Response | Not entered | 1 Participants |
| Cohort 2 (1.0 mg/kg KW-0761IV) Q2W | Overall Response | Stable disease | 2 Participants |
| Cohort 3 (3.0mg/kg KW-0761IV) | Overall Response | Stable disease | 1 Participants |
| Cohort 3 (3.0mg/kg KW-0761IV) | Overall Response | Progressive disease | 4 Participants |
| Cohort 3 (3.0mg/kg KW-0761IV) | Overall Response | Not entered | 0 Participants |
| Cohort 4 (10.0mg/kg KW-0761IV) | Overall Response | Progressive disease | 4 Participants |
| Cohort 4 (10.0mg/kg KW-0761IV) | Overall Response | Not entered | 1 Participants |
| Cohort 4 (10.0mg/kg KW-0761IV) | Overall Response | Stable disease | 1 Participants |